IS5647A - Fastefnalyfjablöndur sem í eru gamma-amínósmjörsýruafleiður, og ferli til að smíða slíkar blöndur - Google Patents

Fastefnalyfjablöndur sem í eru gamma-amínósmjörsýruafleiður, og ferli til að smíða slíkar blöndur

Info

Publication number
IS5647A
IS5647A IS5647A IS5647A IS5647A IS 5647 A IS5647 A IS 5647A IS 5647 A IS5647 A IS 5647A IS 5647 A IS5647 A IS 5647A IS 5647 A IS5647 A IS 5647A
Authority
IS
Iceland
Prior art keywords
mixtures
processes
making
acid derivatives
pharmaceutical preparations
Prior art date
Application number
IS5647A
Other languages
English (en)
Other versions
IS2983B (is
Inventor
Aomatsu Akira
Original Assignee
Warner-Lambert Company, , Delaware Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS5647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner-Lambert Company, , Delaware Corporation filed Critical Warner-Lambert Company, , Delaware Corporation
Publication of IS5647A publication Critical patent/IS5647A/is
Publication of IS2983B publication Critical patent/IS2983B/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IS5647A 1998-05-15 2000-09-29 Fastar lyfjasamsetningar sem innihalda 4-amínó-3-setnar-smjörsýruafleiður valdar úr gabapentíni og/eða pregabalíni og aðferð við að framleiða þær IS2983B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP13311298 1998-05-15
PCT/US1999/010186 WO1999059572A1 (en) 1998-05-15 1999-05-10 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same

Publications (2)

Publication Number Publication Date
IS5647A true IS5647A (is) 2000-09-29
IS2983B IS2983B (is) 2017-09-15

Family

ID=15097099

Family Applications (1)

Application Number Title Priority Date Filing Date
IS5647A IS2983B (is) 1998-05-15 2000-09-29 Fastar lyfjasamsetningar sem innihalda 4-amínó-3-setnar-smjörsýruafleiður valdar úr gabapentíni og/eða pregabalíni og aðferð við að framleiða þær

Country Status (25)

Country Link
US (1) US8623407B2 (is)
EP (1) EP1077691B1 (is)
JP (3) JP4564607B2 (is)
KR (1) KR100669280B1 (is)
CN (1) CN100337687C (is)
AR (1) AR018609A1 (is)
AU (1) AU769038B2 (is)
BR (1) BR9910494B1 (is)
CO (1) CO5060516A1 (is)
CU (1) CU23051A3 (is)
GT (1) GT199900068A (is)
HK (2) HK1036407A1 (is)
HU (1) HU228772B1 (is)
ID (1) ID26395A (is)
IS (1) IS2983B (is)
MY (1) MY127953A (is)
NO (1) NO329116B1 (is)
PA (1) PA8472701A1 (is)
PE (1) PE20000542A1 (is)
PL (1) PL205145B1 (is)
SV (1) SV1999000063A (is)
TW (1) TW592691B (is)
UY (1) UY25513A1 (is)
WO (1) WO1999059572A1 (is)
ZA (1) ZA200006483B (is)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
HUP0301919A3 (en) * 2000-06-16 2006-01-30 Teva Pharma Stable gabapentin having ph within a controlled range
EP1289364B1 (en) * 2000-06-16 2003-12-10 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 2o ppm of chlorine ion
EP1430893A1 (en) * 2000-06-16 2004-06-23 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chloride ion
EP1384473A1 (en) * 2000-06-16 2004-01-28 Teva Pharmaceutical Industries Ltd. Stable gabapentin containing more than 20 ppm of chlorine ion
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
EP1334732B1 (en) * 2000-11-17 2010-06-02 Takeda Pharmaceutical Company Limited Pharmaceutical preparation of n-[2-(1,6,7,8-tetrahydro-2h-indeno[5,4 b]furan-8-yl)ethyl]propionamide coated with a copolyvidone-containing coating free of polyethylene glycol
WO2004032905A1 (en) * 2002-10-08 2004-04-22 Ranbaxy Laboratories Limited Gabapentin tablets and methods for their preparation
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
CN1921839A (zh) * 2004-01-19 2007-02-28 兰贝克赛实验室有限公司 加巴喷丁的稳定缓释口服剂型及其制备方法
NL2000281C2 (nl) 2005-11-02 2007-08-07 Pfizer Prod Inc Vaste farmaceutische samenstellingen die pregabaline bevatten.
KR20080096779A (ko) * 2006-01-20 2008-11-03 다이닛본 스미토모 세이야꾸 가부시끼가이샤 신규 필름 코팅정
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
EP2298286B8 (en) * 2009-09-18 2017-08-09 SiTec PharmaBio SL Process for dewatering of product powders
HU230031B1 (hu) 2010-03-01 2015-05-28 Egis Gyógyszergyár Nyilvánosan Működő Részvénytársaság Pregabalint és izomaltot tartalmazó stabilizált gyógyszerkészítmény
EP2680823B1 (en) * 2011-02-28 2024-05-15 Nano4M Ltd Binder powders
WO2015114509A1 (en) 2014-01-28 2015-08-06 Ranbaxy Laboratories Limited Stabilized gastroretentive tablets of pregabalin
CA2953225A1 (en) 2015-05-26 2016-12-01 Isa Odidi Controlled extended release pregabalin
JP7276760B2 (ja) * 2016-12-08 2023-05-18 日本ケミファ株式会社 ４－アミノ－３－ブタン酸類縁体含有固形製剤
JP6919119B2 (ja) * 2017-01-23 2021-08-18 日新製薬株式会社 ３位が置換されたγ−アミノ酪酸誘導体を含有する圧縮固形医薬組成物。
JP2019052147A (ja) * 2017-09-13 2019-04-04 大原薬品工業株式会社 化学的な安定性が改善された、プレガバリン含有口腔内崩壊錠
JP7138666B2 (ja) * 2018-01-24 2022-09-16 大原薬品工業株式会社 γ－アミノ酪酸誘導体含有錠剤の化学的安定性を改善する方法
MX2020011130A (es) * 2018-04-24 2022-09-09 Shionogi & Co Forma de dosificacion solida que tiene excelente estabilidad.
BR112020021059B1 (pt) 2018-04-24 2022-08-30 Shionogi & Co., Ltd Forma de dosagem sólida

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4115553A (en) * 1973-12-10 1978-09-19 Armour Pharmaceutical Company Antacid tablets
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4087544A (en) 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
US4126684A (en) * 1976-02-11 1978-11-21 Ciba-Geigy Corporation 4-amino-3-p-halophenylbutyric acids and their derivatives used in the control of narcotic abuse
GB8504093D0 (en) * 1985-02-18 1985-03-20 Ici Plc Alkene alkyne/cycloalkylene derivatives
US4486412A (en) * 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
CA1249968A (en) * 1984-04-05 1989-02-14 Kazuo Kigasawa Ointment base
JPS63253022A (ja) * 1987-04-08 1988-10-20 Nitto Electric Ind Co Ltd バクロフエン外用製剤
PH26730A (en) 1988-12-30 1992-09-28 Ciba Geigy Ag Coated adhesive tablets
DE3928183A1 (de) * 1989-08-25 1991-02-28 Goedecke Ag Lactamfreie cyclische aminosaeuren
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
EP0458751A1 (en) * 1990-05-25 1991-11-27 Warner-Lambert Company Delivery system for cyclic amino acids with improved taste, texture and compressibility
US5025035A (en) 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
ES2111659T3 (es) * 1992-03-11 1998-03-16 Asta Medica Ag Comprimidos, granulados y nodulos con alto contenido en sustancias activas para formas de administracion solidas de alta concentracion.
US5510381A (en) 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder

Also Published As

Publication number Publication date
US8623407B2 (en) 2014-01-07
BR9910494B1 (pt) 2011-11-01
UY25513A1 (es) 1999-07-19
HUP0101791A3 (en) 2003-03-28
CO5060516A1 (es) 2001-07-30
NO20005765D0 (no) 2000-11-14
HK1036407A1 (en) 2002-01-04
NO329116B1 (no) 2010-08-30
HUP0101791A2 (hu) 2001-10-28
BR9910494A (pt) 2001-01-09
CN1575817A (zh) 2005-02-09
SV1999000063A (es) 2000-07-31
NO20005765L (no) 2000-11-14
GT199900068A (es) 2002-01-18
AR018609A1 (es) 2001-11-28
JP3527729B2 (ja) 2004-05-17
AU4073399A (en) 1999-12-06
ZA200006483B (en) 2002-04-09
JP3944150B2 (ja) 2007-07-11
JP4564607B2 (ja) 2010-10-20
WO1999059572A1 (en) 1999-11-25
JP2003055211A (ja) 2003-02-26
CN100337687C (zh) 2007-09-19
CU23051A3 (es) 2005-06-24
PL344219A1 (en) 2001-10-08
HU228772B1 (en) 2013-05-28
WO1999059572A8 (en) 2000-12-21
KR20010043610A (ko) 2001-05-25
PL205145B1 (pl) 2010-03-31
EP1077691B1 (en) 2008-09-10
KR100669280B1 (ko) 2007-01-17
JP2004043506A (ja) 2004-02-12
ID26395A (id) 2000-12-21
MY127953A (en) 2007-01-31
JP2000034227A (ja) 2000-02-02
PE20000542A1 (es) 2000-08-10
EP1077691A1 (en) 2001-02-28
AU769038B2 (en) 2004-01-15
HK1072729A1 (en) 2005-09-09
IS2983B (is) 2017-09-15
TW592691B (en) 2004-06-21
US20090156677A1 (en) 2009-06-18
PA8472701A1 (es) 2000-09-29

Similar Documents

Publication Publication Date Title
IS5647A (is) Fastefnalyfjablöndur sem í eru gamma-amínósmjörsýruafleiður, og ferli til að smíða slíkar blöndur
DK1117645T3 (da) Arylsubstituerede propanolaminderivater, fremgangsmåder til fremstilling deraf, lægemidler indeholdende disse forbindelser og anvendelse deraf
NO964700D0 (no) Nye aminosyrederivater, fremgangsmåte til deres fremstilling og farmasöytiske blandinger som inneholder disse forbindelser
NO20001409L (no) Karboksamidotiazolderivater, fremgangsmÕte for fremstilling derav og farmasøytiske blandinger
IS5666A (is) Faststilltar lyfjablöndur úr gamma-amínósmjörsýruafleiðum og ferli til að smíða þær
NO991130D0 (no) Modifiserte aminosyrer, farmas°ytiske preparater som inneholder disse forbindelsene og fremgangsmÕter for fremstilling derav
AU4710499A (en) Cyclic amino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use ofsuch compounds
IL142531A0 (en) Cyclic peptide compound, processes for the preparation thereof and pharmaceutical compositions containing the same
DK0885204T3 (da) Nye arylglycinamidderivater, fremgangsmåde til fremstilling deraf og farmaceutiske præparater indeholdende disse forbindelser
NO20005430D0 (no) 1-[(1-substituerte-4-piperidinyl)metyl]-4-piperidinderivater, fremgangsmÕter for fremstilling av disse, medisinske preparater inneholdende dem, og mellomprodukter
IL143801A0 (en) (hetero) aryl-bicyclic heteroaryl derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL138969A0 (en) Anthranilic acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL140897A0 (en) Benzocycloheptene derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
IL139529A0 (en) Platinum complexes, processes for the preparation thereof and pharmaceutical compositions containing the same
HUP9903336A3 (en) Substituted sulfonic acid n-[(aminoiminomethyl)phenylalkyl]-azaheterocyclamide compounds and pharmaceutical compositions containing the same
HUP0002171A3 (en) Aminophosphonic acid derivatives, method for their preparation and pharmaceutical compositions thereof
IS5958A (is) 3, 4, 5-þrístaðgengin arýlnítronefnasambönd og lyfjablöndur sem slík efnasambönd eru í
NO20006646L (no) Aminosyrederivater og legemidler inneholdende de samme som aktiv bestanddel
DK1049721T3 (da) Syntetiske polysaccharider, fremgangsmåde til fremstilling heraf og farmaceutiske præparater indeholdende disse
DK1117642T3 (da) Substituerede 1,3-diaryl-2-pyridin-2-yl-3-(pyridin-2-ylamino)-propanolderivater, fremgangsmåder til fremstilling deraf, farmaceutiske præparater indeholdende dem og anvendelse deraf
DK0838469T3 (da) 10,13,15-trioxatricyclo(9.2.1 9.6)-pentadecanon-derivater, fremgangsmåde til deres fremstilling og lægemidler indeholdende disse forbindelser
IS1897B (is) Lyfjablöndur sem fela í sér kirnishliðstæður sem eru hentugar til frostþurrkunar
NO955320L (no) Substituerte 4-fenyltiazolderivater, fremgangsmåte for fremstilling derav og farmasöytiske blandinger som inneholder dem
NO960272L (no) Oksatiolaner, fremgangsmåte for deres fremstilling og farmasöytiske preparater som inneholder de samme
IL139528A0 (en) Platinum complexes, processes for the preparation thereof and pharmaceutical compositions containing the same